These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11200764)

  • 21. Nonheparin anticoagulants for heparin-induced thrombocytopenia.
    Kelton JG; Arnold DM; Bates SM
    N Engl J Med; 2013 Feb; 368(8):737-44. PubMed ID: 23425166
    [No Abstract]   [Full Text] [Related]  

  • 22. Ardeparin and danaparoid.
    Dimens Crit Care Nurs; 2000; 19(4):13-4. PubMed ID: 11998151
    [No Abstract]   [Full Text] [Related]  

  • 23. Thromboembolic complications in a patient with heparin-induced thrombocytopenia (HIT) showing cross-reactivity to a low molecular weight heparin-treatment with Org 10172 (Lomoparan).
    Muhm M; Claeys L; Huk I; Koppensteiner R; Kyrle PA; Minar E; Stümpflen A; Ehringer H; Polterauer P
    Wien Klin Wochenschr; 1997 Feb; 109(4):128-31. PubMed ID: 9076930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
    Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
    Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of danaparoid anticoagulation for cardiopulmonary bypass.
    Ariano RE; Bhattacharya SK; Moon M; Brownell LG
    J Thorac Cardiovasc Surg; 2000 Jan; 119(1):167-8. PubMed ID: 10612777
    [No Abstract]   [Full Text] [Related]  

  • 26. Preventing complications in heparin-induced thrombocytopenia. Alternative anticoagulants are improving patient outcomes.
    Rice L; Nguyen PH; Vann AR
    Postgrad Med; 2002 Sep; 112(3):85-9. PubMed ID: 12360660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Heparin induced thrombocytopenia: case report with acute thrombotic complications and literature review].
    Plassat R; Cognet F; Ternisien C; Ménoret N; Dubus-Bausière V; Brunel P; Bontoux L; Bernat C; Richard I
    Ann Readapt Med Phys; 2002 May; 45(5):216-23. PubMed ID: 12020989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
    Hale LP; Smith K; Braden GA; Owen J
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):318-22. PubMed ID: 9829897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-induced thrombocytopenia presenting after the cessation of low molecular weight heparin prophylaxis with enoxaparin.
    Barratt SM; Ruff SJ; Edwards RC
    Med J Aust; 2000 May; 172(9):449. PubMed ID: 10870540
    [No Abstract]   [Full Text] [Related]  

  • 30. Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
    Burkhard-Meier U; Söhngen D; Schultheiss HP; Greinacher A; Schwartzkopff B; Vogt M; Heyll A; Schneider W
    Intensive Care Med; 1995 Jun; 21(6):542-3. PubMed ID: 7560499
    [No Abstract]   [Full Text] [Related]  

  • 31. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Two surgical case reports showing atypical heparin-induced thrombocytopenia].
    Höhnke C; Haas S
    Chirurg; 2007 Feb; 78(2):138, 140-1. PubMed ID: 17252251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed-type skin reaction to the heparin-alternative danaparoid.
    Szolar-Platzer C; Aberer W; Kränke B
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 2):920-2. PubMed ID: 11044823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low molecular weight heparins and heparinoids.
    Eikelboom JW; Hankey GJ
    Med J Aust; 2002 Oct; 177(7):379-83. PubMed ID: 12358583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M; Magnani HN; Lindhoff-Last E
    Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy.
    Davenport A
    Am J Kidney Dis; 1998 Oct; 32(4):E3. PubMed ID: 10074589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIT/HITT and alternative anticoagulation: current concepts.
    Lakshmanan S; Saha B; Rittoo D
    Br J Anaesth; 2003 Sep; 91(3):445; author reply 445-6. PubMed ID: 12966934
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
    Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
    Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.
    Jackson MR; Danby CA; Alving BM
    Ann Thorac Surg; 1997 Dec; 64(6):1815-7. PubMed ID: 9436582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed cutaneous reaction to unfractionated heparin, low molecular weight heparin and danaparoid.
    Sivakumaran M; Ghosh K; Munks R; Gelsthorpe K; Tan L; Wood JK
    Br J Haematol; 1994 Apr; 86(4):893-4. PubMed ID: 7802799
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.